🌊 The $2 Trillion ETF Tsunami: How to Invest When the Market Looks Expensive 🛡️
ETFs have transformed investing.
They're cheaper.
Smarter.
More diversified.
But one question remains:
Can the world's greatest investment vehicle still produce disappointing returns if the assets inside it are expensive?
With Goldman Sachs forecasting more than $2 trillion of ETF inflows while the S&P 500 trades at roughly twice its historical average valuation, disciplined portfolio construction has rarely mattered more.
📹 Zoom (ZM): Wall Street Still Thinks It's a Video Company. What If It's Becoming an AI Platform? 🤖
Wall Street still sees Zoom as a pandemic-era video conferencing company.
We think that narrative is becoming outdated.
With a fortress balance sheet, nearly $1.7 billion in annual free cash flow, AI Companion, Zoom Phone, Contact Center and Workvivo, Zoom may quietly be evolving into a broader enterprise communications platform.
💼 Goldman Sachs (GS): One Year Later—When a Great Investment Becomes a Great Company
Last year, insider buying and an attractive valuation made Goldman Sachs one of our favorite ideas. The stock has since more than doubled. Here's why the business remains exceptional—but the investment opportunity has fundamentally changed.
🧬 Moderna (NASDAQ: MRNA) Stock Analysis: Why We Still Believe This mRNA Pioneer Is Undervalued
Moderna has already doubled from its 2025 lows, yet we believe the story is still in its early chapters. Science Day confirmed that Moderna is becoming far more than a vaccine company—it's building one of biotechnology's most ambitious programmable medicine platforms.
🦸♂️ The Attic of the Soul: Why Your $9M “Super Moment” Is Covered in Dust
A dusty attic revealed a $9.1M treasure. Most of us have something similar—buried ideas, talents, or ambitions waiting to be rediscovered. The question is: will you climb the ladder?
S&P 500 PE Ratio Hits 30: Is a 2026 Bear Market Black Swan Immersion Imminent?
With the S&P 500 trading at nearly twice its historical P/E average, valuations are stretched. Even a 20% drop wouldn’t make stocks cheap. Is 2026 the year gravity reasserts itself?
No Bullish Trigger: Ginkgo Bioworks Should Read “Ginkgo Bio… Doesn’t Work”
Ginkgo Bioworks (DNA) has ambitious science and flashy AI rhetoric — but declining revenues, deep losses, and no insider conviction make this a tough stock to love. 🧬📉
Could Darling Become One? Shares Jump on an Ingredients-Fueled Beat
From fryer oil to future fuel: DAR beat on sales, guided core EBITDA to $875–900M, and is monetizing PTCs while prepping SAF scale-up. Fun + smart breakdown with TL;DR & FAQs.
Funds and Analysts Love BioMarin Pharmaceutical (BMRN), A Rare Combo of Value and Growth Fighting Also Rare Genetic Diseases. Should You?
BioMarin is that rare biotech: profits, pipeline, and price discipline. VOXZOGO grows, margins expand, and catalysts stack—at a surprisingly modest valuation.
Year-Old CEO Could Start Making an Impact: Can Teladoc (TDOC) Reboot Growth, Turn a Profit, and Send Its Stock Back to the Moon?
Teladoc Health is down 97% from ATH — but Citron says Livongo is booming, institutions are buying, and the CEO just hit his one-year mark. Bargain bin or value trap?